Clinical Trial Update: Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial to mitigate immune-mediated loss of response to asfotase alfa (STRENSIQ) for hypophosphatasia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypophosphatasia

Drugs mentioned

• STRENSIQ (asfotase alfa)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hypophosphatasia | Phase 4 | Status: WITHDRAWN